

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

AMARIN PHARMA, INC., AMARIN  
PHARMACEUTICALS IRELAND  
LIMITED, MOCHIDA  
PHARMACEUTICAL CO., LTD.,

Plaintiffs,

v.

HIKMA PHARMACEUTICALS USA  
INC., HIKMA PHARMACEUTICALS  
PLC,

Defendants.

C.A. No. 20-1630-RGA

**PLAINTIFFS' RESPONSE IN OPPOSITION TO  
DEFENDANTS' MOTION TO DISMISS**

Dated: February 10, 2021

Jeremy D. Anderson (No. 4515)  
FISH & RICHARDSON P.C.  
222 Delaware Avenue, 17<sup>th</sup> Floor  
Wilmington, DE 19899  
Tel: (302) 652-5070  
janderson@fr.com

Elizabeth M. Flanagan (No. 5891)  
Michael Kane  
Deanna J. Reichel  
60 South Sixth Street, Suite 3200  
Minneapolis, MN 55402  
(612) 335-5070  
eflanagan@fr.com; kane@fr.com;  
reichel@fr.com

Jonathan E. Singer  
12860 El Camino Real, Suite 400  
San Diego, CA 92130  
(858) 678-5070  
singer@fr.com

*Attorneys for Plaintiffs  
Amarin Pharma, Inc.; Amarin  
Pharmaceuticals Ireland Limited,  
Mochida Pharmaceutical Co., Ltd.*

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
I. NATURE AND STAGE OF THE PROCEEDINGS .....	1
II. SUMMARY OF THE ARGUMENT .....	1
III. STATEMENT OF THE FACTS .....	3
A. Amarin Surprisingly Demonstrates VASCEPA® Reduces Cardiovascular Risk and Obtains Patents for that Use .....	3
B. Upon Approval of the CV Indication, FDA Allowed Amarin to Remove the CV Limitation of Use from the VASCEPA® Label .....	5
C. Hikma Launches a Generic Copy of VASCEPA® and Promotes It for the Patented Uses .....	6
1. Hikma’s Label Promotes and Encourages Use of The Patented Methods.....	6
2. Hikma’s Marketing and Promotional Statements Promote and Encourage Use of the Patented Methods .....	8
3. Hikma Launched Its Generic with the Intention It Be Used To Infringe.....	9
IV. LEGAL STANDARD.....	11
V. ARGUMENT .....	12
A. Hikma’s Motion Should Be Denied under Controlling Precedent .....	12
1. Amarin Plausibly Alleges that Hikma’s Label Instructs Others to Infringe the Patented Methods .....	13
2. Amarin Plausibly Alleges that Hikma’s Additional Actions, Including Its Marketing Materials, Further Support Inducement .....	15
B. Hikma’s Bases for Dismissal Are Unavailing .....	17
VI. CONCLUSION.....	20

**TABLE OF AUTHORITIES**

	<b><u>Page(s)</u></b>
<b>Cases</b>	
<i>Amarin Pharma Inc. v. Hikma Pharms. USA Inc.</i> , 449 F. Supp. 3d 967 (D. Nev. 2020).....	14
<i>Arthrocare Corp. v. Smith &amp; Nephew, Inc.</i> , 406 F.3d 1365 (Fed. Cir. 2005).....	16
<i>Ashcroft v. Iqbal</i> , 556 U.S. 662 (2009).....	12
<i>AstraZeneca LP v. Apotex, Inc.</i> , 633 F.3d 1042 (Fed. Cir. 2010).....	2, 12, 13, 14
<i>AstraZeneca LP v. Apotex, Inc.</i> , 669 F.3d 1370 (Fed. Cir. 2012).....	17
<i>Bayer Schering Pharma AG v. Lupin, Ltd.</i> , 676 F.3d 1316 (Fed. Cir. 2012).....	17
<i>Bell Atlantic Corp. v. Twombly</i> , 550 U.S. 544 (2007).....	11, 12
<i>In re Burlington Coat Factory Sec. Litig.</i> , 114 F.3d 1410 (3d Cir. 1997).....	12
<i>DSU Med. Corp. v. JMS Co.</i> , 471 F.3d 1293 (Fed. Cir. 2006).....	12, 16
<i>Enzo Life Sciences, Inc. v. Digene Corp.</i> , 295 F. Supp. 2d 424 (D. Del. 2003).....	11
<i>Ericsson, Inc. v. D-Link Systems, Inc.</i> , 773 F.3d 1201 (Fed. Cir. 2014).....	16
<i>Fairchild Semiconductor Corp. v. Power Integrations, Inc.</i> , 935 F. Supp. 2d 772 (D. Del. 2013).....	12
<i>GlaxoSmithKline LLC v. Teva Pharm. USA, Inc.</i> , 976 F.3d 1347 (Fed. Cir. 2020).....	20
<i>Global-Tech Appliances, Inc. v. SEB S.A.</i> , 563 U.S. 754 (2011).....	19

**TABLE OF AUTHORITIES (cont'd)**

	<b><u>Page(s)</u></b>
<i>Grunenthal GMBH v. Alkem Labs. Ltd.</i> , 919 F.3d 1333 (Fed. Cir. 2019).....	18, 19
<i>HZNP Medicines LLC v. Actavis Labs.</i> , 940 F.3d 680 (Fed. Cir. 2019).....	18, 19
<i>Johns Hopkins Univ. v. Alcon Labs. Inc.</i> , No. CV 15-525, 2018 WL 4178159 (D. Del. Aug. 30, 2018) .....	9
<i>Mentor H/S, Inc. v. Med. Device All., Inc.</i> , 244 F.3d 1365 (Fed. Cir. 2001).....	16
<i>Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd.</i> , 545 U.S. 913 (2005).....	2, 3, 12, 15
<i>Novartis Pharm. Corp. v. Actavis, Inc.</i> , No. 12–366–RGA–CJB, 2012 WL 6212619 (D. Del. Dec. 5, 2012) .....	17
<i>Power Integrations, Inc. v. Fairchild Semiconductor International, Inc.</i> , 843 F.3d 1315 (Fed. Cir. 2016).....	16
<i>Sanofi v. Watson Labs. Inc.</i> , 875 F.3d 636 (Fed. Cir. 2017).....	14, 15
<i>Takeda Pharmaceuticals U.S.A., Inc. v. West-Ward Pharmaceuticals Corp.</i> , 188 F. Supp. 3d 367 (D. Del. 2016).....	17, 18
<i>Takeda Pharmaceuticals U.S.A., Inc. v. West-Ward Pharmaceuticals Corp.</i> , 785 F.3d 625 (Fed. Cir. 2015).....	17, 18
<i>Toshiba Corp. v. Imation Corp.</i> , 681 F.3d 1358 (Fed. Cir. 2012).....	16
<b>Statutes</b>	
21 U.S.C. § 355(j)(2)(A)(viii).....	6

**TABLE OF AUTHORITIES (cont'd)**

	<b><u>Page(s)</u></b>
<b>Other Authorities</b>	
Federal Rule of Civil Procedure 12 .....	17
Federal Rule of Evidence 407 .....	9

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.